Ranibizumab for treating choroidal neovascularisation associated with pathological myopia

  • Technology appraisal guidance
  • TA298
  • Published: 
  • Last updated: 
Download (PDF)

What has NICE said?

Ranibizumab is recommended as a possible treatment for sight problems caused by choroidal neovascularisation in people who also have pathological myopia.

What does this mean for me?

If you have choroidal neovascularisation and pathological myopia, and your doctor thinks that ranibizumab is the right treatment, you should be able to have the treatment on the NHS.

Ranibizumab should be available on the NHS within 3 months of the guidance being issued.

  • Information Standard

This page was last updated: